https://allsci.com/news/licensing-and-partnerships/omniab-eli-lilly-deal-secures-usd-370m-milestone/ AllScien 2026-08-17T16:25:49.399249Z Lilly taps OmniAb for ion channel discovery in deal worth up to USD 370m https://allsci.com/news/ipo-public-listing/slate-medicines-ipo-merger-goes-public-via/ AllScien 2026-08-17T16:19:48.386964Z Slate Medicines goes public via Fulcrum merger to challenge PACAP migraine field https://allsci.com/news/clinical-trials/duravyu-wet-amd-trial-eyepoints-misses-primary/ AllScien 2026-08-17T16:14:48.558007Z EyePoint's Duravyu misses wet AMD primary endpoint, hinges on second trial for FDA path https://allsci.com/news/preclinical/namodenoson-pancreatic-cancer-can-fites-boosts/ AllScien 2026-08-17T16:11:02.368633Z Can-Fite's namodenoson boosts gemcitabine potency in pancreatic cancer preclinical models https://allsci.com/news/clinical-trials/bispecific-car-t-lymphoma-abelzeta-reclaims/ AllScien 2026-08-17T15:59:50.137252Z J&J hands C-CAR039 back to AbelZeta amid pivot toward in vivo CAR-T https://allsci.com/news/licensing-and-partnerships/immune-cell-therapy-partnership-biocytics-and/ AllScien 2026-08-17T15:50:28.263486Z BioCytics and LIDE Biotech partner to validate immune cell therapies in patient-derived tumor models https://allsci.com/news/venture-financing/glutaminase-inhibitor-schizophrenia-leal/ AllScien 2026-08-17T15:22:10.812704Z Leal Therapeutics raises USD 30m to advance glutaminase inhibitor in schizophrenia https://allsci.com/news/clinical-trials/volrustomig-trial-discontinuation-astrazeneca/ AllScien 2026-08-17T15:13:53.827710Z AstraZeneca drops Phase III volrustomig trial after pembrolizumab challenge fails https://allsci.com/news/research/friedreichs-ataxia-treatment-myeloid-cell/ AllScien 2026-08-17T14:56:57.831598Z Myeloid cell transplantation rescues Friedreich's ataxia through mitochondrial transfer in mice https://allsci.com/news/preclinical/hdac-inhibition-cancer-university-of-pittsburgh/ AllScien 2026-08-17T14:26:31.703840Z Pitt, Magee-Womens team turns cancer dormancy into a druggable vulnerability https://allsci.com/news/research/polyamines-ferroptosis-whitehead-institute/ AllScien 2026-08-17T13:53:34.219382Z Cell study uncovers polyamines as natural ferroptosis defense https://allsci.com/news/licensing-and-partnerships/oral-peptide-therapeutics-ai-aizen-applies/ AllScien 2026-08-17T12:59:34.375538Z Aizen lands multi-program oral peptide deal worth up to USD 100m per target https://allsci.com/news/funding/silence-therapeutics-divesiran-funding-raises-usd-1/ AllScien 2026-08-17T12:44:54.892958Z Silence Therapeutics completes private fund raise at USD 201.3m for divesiran trial https://allsci.com/news/licensing-and-partnerships/sandoz-henlius-biosimilars-partnership-expands-to/ AllScien 2026-08-17T12:42:20.516498Z Sandoz expands Henlius partnership to cover up to 10 biosimilars for USD 322m https://allsci.com/news/clinical-trials/efgartigimod-phase-iii-imnm-wins-first-trial-in/ AllScien 2026-08-17T11:27:58.918305Z argenx's Vyvgart Hytrulo delivers first Phase III success in IMNM https://allsci.com/news/clinical-trials/egfr-mutated-lung-cancer-met-resistance/ AllScien 2026-08-17T10:51:52.551160Z Tagrisso plus Orpathys extends OS in MET-resistant EGFR-mutated lung cancer https://allsci.com/news/clinical-trials/enhertu-her2-lung-cancer-becomes-first/ AllScien 2026-08-17T10:49:38.894321Z Enhertu becomes first HER2-directed therapy to beat chemoimmunotherapy in 1st-line lung cancer https://allsci.com/news/clinical-trials/tau-gene-therapy-alzheimers-voyager-advances/ AllScien 2026-08-17T10:45:16.774595Z Voyager registers first-in-human trial of tau-silencing gene therapy VY1706 in Alzheimer’s https://allsci.com/news/regulatory/ich-e6r3-gcp-guidance-china-chinas-nmpa-opens/ AllScien 2026-08-17T09:27:14.926035Z China moves quickly on ICH E6(R3) Annex 2 with March applicability date https://allsci.com/news/research/nmpa-national-key-rd-program-rules-seeks-public/ AllScien 2026-08-17T09:21:03.754745Z China NMPA sets framework for direct role in national R&D funding